Internal Medicine, Endocrinology, Diabetes, & Metabolism · Houston, TX
NPI
1578658001
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5711 Almeda Rd
Houston, TX, 77004
Phone (713) 520-8385
Groups this clinician bills Medicare through
Medicare paid, 2024
$349K
9,229 services
Medicare patients, 2024
531
Average age 74
Drug cost, 2024
$4.3M
12,876 prescriptions
Company payments, 2025
$3,214
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gerardo Bueso was code 99213 (office e&m - established), 1,470 times for 464 patients. In total Gerardo Bueso billed 9,229 services in 66 codes, and Medicare paid $349K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-09-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,470 | 464 | $59.98 | $88K |
| 99423 E&M - Miscellaneous | Office | 1,418 | 54 | $35.25 | $50K |
| 82962 Clinical Chemistry | Office | 1,098 | 293 | $3.20 | $3,519 |
| 83036 Blood Count | Office | 661 | 275 | $9.52 | $6,293 |
| 99422 Office/Outpatient Services | Office | 628 | 50 | $22.15 | $14K |
| 99457 E&M - Miscellaneous | Office | 490 | 54 | $36.90 | $18K |
| 99232 Hospital E&M - Subsequent | Facility | 469 | 47 | $59.45 | $28K |
| 99454 E&M - Miscellaneous | Office | 388 | 53 | $35.21 | $14K |
| 71046 X-ray - Chest | Office | 312 | 262 | $20.70 | $6,459 |
| 99214 Office E&M - Established | Office | 264 | 194 | $76.47 | $20K |
| 93000 Electrocardiogram | Office | 214 | 197 | $8.33 | $1,782 |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 195 | 195 | $17.79 | $3,469 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 195 | 195 | $123.05 | $24K |
| 95251 Test - Miscellaneous | Office | 140 | 66 | $24.03 | $3,365 |
| 81003 Clinical Chemistry | Office | 134 | 107 | $2.20 | $295 |
By year: 2022 $669K for 9,337 services; 2023 $489K for 15,619 services; 2024 $349K for 9,229 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 1,098 | 293 | $3.20 | $3,519 |
| 83036 Blood Count | 661 | 275 | $9.52 | $6,293 |
| 81003 Clinical Chemistry | 134 | 107 | $2.20 | $295 |
| 82044 Clinical Chemistry | 38 | 38 | $6.11 | $232 |
| 82570 Clinical Chemistry | 38 | 38 | $5.08 | $193 |
Medicare prescription drug claims, 2024
In 2024, the drug Gerardo Bueso prescribed most often to Medicare patients was Ozempic (Semaglutide), with 888 prescriptions and refills. In total Gerardo Bueso wrote 12,876 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 888 | 1,697 | 231 | $1.6M |
| Metformin Hcl Generic | 848 | 2,448 | 286 | $6,378 |
| Levothyroxine Sodium Generic | 692 | 1,913 | 197 | $7,459 |
| Atorvastatin Calcium Generic | 664 | 1,942 | 206 | $6,292 |
| Rosuvastatin Calcium Generic | 446 | 1,284 | 162 | $6,836 |
| Amlodipine Besylate Generic | 441 | 1,274 | 150 | $3,219 |
| Losartan Potassium Generic | 357 | 1,028 | 115 | $3,670 |
| Lisinopril Generic | 240 | 699 | 73 | $2,135 |
| Farxiga Dapagliflozin Propanediol | 233 | 522 | 71 | $281K |
| Glipizide Generic | 187 | 553 | 61 | $2,494 |
| Omeprazole Generic | 177 | 505 | 59 | $3,161 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 176 | 478 | 90 | $21K |
| Jardiance Empagliflozin | 170 | 400 | 64 | $229K |
| Trulicity Dulaglutide | 164 | 263 | 45 | $250K |
| Tresiba Flextouch U-100 Insulin Degludec | 159 | 413 | 52 | $75K |
Brand drugs: 3,924 claims; generic drugs: 8,516 claims; opioid claims: 86.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gerardo Bueso $3,214 ($3,214 in general payments such as food, travel and fees) from 30 companies. The largest payer was Corcept Therapeutics with $344.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 17 | $344 |
| Ascendis Pharma Endocrinology Inc ASND | 12 | $310 |
| Novo Nordisk Inc NVO | 16 | $281 |
| Mannkind Corporation MNKD | 14 | $272 |
| Recordati_rare_diseases_inc. | 10 | $234 |
| Amgen Inc. AMGN | 13 | $213 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 13 | $208 |
| Lilly USA, LLC LLY | 10 | $186 |
| Abbott Laboratories ABT | 12 | $165 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $129 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.